自动化虚拟现实认知治疗与虚拟现实心理放松治疗持续性被害妄想的精神病患者的比较:THRIVE平行组单盲随机对照试验及中介分析
THRIVE试验在英格兰4家NHS信托机构纳入80例持续性被害妄想的精神病患者,随机分配至VR认知治疗或VR心理放松治疗,均辅助常规照护。
要点
- VR认知治疗与VR心理放松治疗在改善被害妄想确信度上无显著差异。
- 两种VR干预的Credibility与Expectancy评分无显著差异,依从率均达85%。
- 防御行为减少与安全感信念增加在两组间亦无显著差异。
核心结论
- 两种VR干预效果相似,尽管设计针对不同机制,均与被害妄想大幅改善相关但不能确定归因于治疗。
- 沉浸式技术对严重精神健康问题有前景,但需进一步实验研究不同治疗技术及潜在机制。
研究设计与样本
- THRIVE为平行组、单盲、随机对照试验,在英格兰4家NHS信托机构进行。
- 纳入80例年龄≥16岁、持续性被害妄想至少3个月且确信度≥50%、在户外与他人相处时感到威胁、转诊临床团队诊断为非情感性精神病性障碍的患者。
- 按1:1随机分配至VR认知治疗(39例)或VR心理放松治疗(41例),使用置换区组算法并按妄想严重度分层,所有参与者继续常规照护。
- 每种VR治疗约4周内提供4次 sessions,由助理心理学家或临床心理学家支持,评估者在0、2、4(主要终点)、8、16、24周盲法评估。
- 主要结局为PSYRATS评估的被害妄想确信度(0-100%),在意向性治疗人群中分析。
主要发现
- 共纳入80例参与者:49例(61%)男性,31例(39%)女性,平均年龄40岁(SD 13,范围18-73),64例(80%)白人。
- VR认知治疗组33例(85%)完成全部4次 sessions,VR心理放松组35例(85%)完成全部4次 sessions。
关键数值与推荐
- 持续性被害妄想定义为至少持续3个月且确信度≥50%。
- 主要终点为第4周(治疗结束)PSYRATS评估的被害妄想确信度(0-100%)。
- 治疗可信度与结局期望采用参与者评分,无显著组间差异。
临床怎么用
- VR认知治疗与VR心理放松治疗均可作为辅助常规照护的可行干预,两者依从性高且耐受良好。
- 临床选择VR干预时需注意两种方案在本试验中疗效无显著差异,不能确定症状改善归因于特定治疗机制。
- 对持续性被害妄想的精神病患者,VR干预实施需由助理心理学家或临床心理学家支持,约4周内完成4次 sessions。
局限性
- 样本量较小(80例),可能不足以检测组间微小差异。
- 两种VR干预均与大幅改善相关,但无法确定改变是否由治疗本身所致。
- 试验因COVID-19大流行限制于2020年3月16日至9月14日暂停,可能影响实施。
- 研究未设常规照护单独对照组,无法分离VR干预的特异性效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persecutory delusions are a major psychiatric problem that often do not respond sufficiently to standard pharmacological or psychological treatments. We developed a new brief automated virtual reality (VR) cognitive treatment that has the potential to be used easily in clinical services. We aimed to compare VR cognitive therapy with an alternative VR therapy (mental relaxation), with an emphasis on understanding potential mechanisms of action. METHODS: THRIVE was a parallel-group, single-blind, randomised controlled trial across four UK National Health Service trusts in England. Participants were included if they were aged 16 years or older, had a persistent (at least 3 months) persecutory delusion held with at least 50% conviction, reported feeling threatened when outside with other people, and had a primary diagnosis from the referring clinical team of a non-affective psychotic disorder. We randomly assigned (1:1) patients to either THRIVE VR cognitive therapy or VR mental relaxation, using a permuted blocks algorithm with randomly varying block size, stratified by severity of delusion. Usual care continued for all participants. Each VR therapy was provided in four sessions over approximately 4 weeks, supported by an assistant psychologist or clinical psychologist. Trial assessors were masked to group allocation. Outcomes were assessed at 0, 2 (therapy mid-point), 4 (primary endpoint, end of treatment), 8, 16, and 24 weeks. The primary outcome was persecutory delusion conviction, assessed by the Psychotic Symptoms Rating Scale (PSYRATS; rated 0-100%). Outcome analyses were done in the intention-to-treat population. We assessed the treatment credibility and expectancy of the interventions and the two mechanisms (defence behaviours and safety beliefs) that the cognitive intervention was designed to target. This trial is prospectively registered with the ISRCTN registry, ISRCTN12497310. FINDINGS: From Sept 21, 2018, to May 13, 2021 (with a pause due to COVID-19 pandemic restrictions from March 16, 2020, to Sept 14, 2020), we recruited 80 participants with persistent persecutory delusions (49 [61%] men, 31 [39%] women, with a mean age of 40 years [SD 13, range 18-73], 64 [80%] White, six [8%] Black, one [1%] Indian, three [4%] Pakistani, and six [8%] other race or ethnicity). We randomly assigned 39 (49%) participants assigned to VR cognitive therapy and 41 (51%) participants to VR mental relaxation. 33 (85%) participants who were assigned to VR cognitive therapy attended all four sessions, and 35 (85%) participants assigned to VR mental relaxation attended all four sessions. We found no significant differences between the two VR interventions in participant ratings of treatment credibility (adjusted mean difference -1·55 [95% CI -3·68 to 0·58]; p=0·15) and outcome expectancy (-0·91 [-3·42 to 1·61]; p=0·47). 77 (96%) participants provided follow-up data at the primary timepoint. Compared with VR mental relaxation, VR cognitive therapy did not lead to a greater improvement in persecutory delusions (adjusted mean difference -2·16 [-12·77 to 8·44]; p=0·69). Compared with VR mental relaxation, VR cognitive therapy did not lead to a greater reduction in use of defence behaviours (adjusted mean difference -0·71 [-4·21 to 2·79]; p=0·69) or a greater increase in belief in safety (-5·89 [-16·83 to 5·05]; p=0·29). There were 17 serious adverse events unrelated to the trial (ten events in seven participants in the VR cognitive therapy group and seven events in five participants in the VR mental relaxation group). INTERPRETATION: The two VR interventions performed similarly, despite the fact that they had been designed to affect different mechanisms. Both interventions had high uptake rates and were associated with large improvements in persecutory delusions but it cannot be determined that the treatments accounted for the change. Immersive technologies hold promise for the treatment of severe mental health problems. However, their use will likely benefit from experimental research on the application of different therapeutic techniques and the effects on a range of potential mechanisms of action. FUNDING: Medical Research Council Developmental Pathway Funding Scheme and National Institute for Health and Care Research Oxford Health Biomedical Research Centre.
引用
- Freeman D, Lister R, Waite F, et al. Automated virtual reality cognitive therapy versus virtual reality mental relaxation therapy for the treatment of persistent persecutory delusions in patients with psychosis (THRIVE): a parallel-group, single-blind, randomised controlled trial in England with mediation analyses. Lancet Psychiatry. 2023. PMID: 37742702. doi:10.1016/S2215-0366(23)00257-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。